Improving P. aeruginosa detection with Breath-based diagnostics (IMPACT-Breath)
Principal Investigator
Study Number
SFD20001
Summary
For each expectorating subject, the diagnostic accuracy of the volatile biomarker panel will be tested (with sputum culture as the standard). We hypothesize that volatile biomarker panels in breath are sensitive and specific for P. aeruginosa lung infections in Cystic Fibrosis patients, irrespective of a patient?s prior P. aeruginosa infection history or the presence of other markers. 2: Quantify intra-subject breath variability of the target pediatric population (Longitudinal). We will collect longitudinal breath samples for one to two years from P. aeruginosa-negative subjects (n = 58 25% non-expectorating) at 4 pediatric CF clinical centers. We will measure intra-subject variance in the breath signatures of expectorating and non-expectorating subjects.
Phase
N/A
Contact
Available at the following location(s)
- Lebanon
Do you need help with some of the labels on this page?
Read our glossary of terms